36 results about "Lipopolysaccharide" patented technology

This invention relates to the use of a natural terpene compound in pharmaceuticals, said natural terpene compound having the structure shown in formula (I), and having the function of preparing a compound for the prevention or treatment of hypoxia-inducible factor-1. α Use in medicines for diseases associated with abnormally elevated activity. This invention has discovered that the compound possesses hypoxia-inducible factor-1. α It exhibits inhibitory activity, effectively suppressing macrophage inflammatory responses and hepatocyte damage. It also demonstrates significant protective function against lipopolysaccharide / galactosamine-induced acute liver injury in mice, and can be used as a lead compound for the preparation of new drugs or drugs for the prevention and treatment of acute liver injury.

The application relates to a method for constructing a rat model of chronic obstructive pulmonary disease (COPD) related pulmonary arterial hypertension and application thereof, and belongs to the technical field of animal disease model construction. The method selects 6-8-week-old, 220+ / -10g healthy male SD rats, and all the rats are adaptively fed in a standard SPF level animal room for 7 days; then the rats are divided into a Con group and a COPD-PH group; the rats in the COPD-PH group are given 1mg / mL lipopolysaccharide by airway instillation on the first day and the 14th day; the rats are placed in a self-made whole-body inhalation smoking box for 1h every day from the 2nd day to the 13th day and from the 15th day to the 30th day; the rats enter a low-oxygen box for 8h every day during the light period from the 2nd day to the 13th day and from the 15th day to the 30th day; the rat model can simultaneously reproduce the characteristics of COPD and typical changes of pulmonary arterial hypertension, the right ventricular systolic pressure can be stably increased to 40-50mmHg, the right ventricular hypertrophy index can reach 0.40-0.50, the pulmonary vascular remodeling and inflammation are significant, and various indexes are stable and good in repeatability.

This invention discloses a compound soft capsule based on camellia oil and its preparation method, belonging to the field of health food processing technology. Using camellia oil as the core carrier, this invention combines extracts of honeysuckle, green tea, and licorice root, using beeswax as a specific suspending agent, without adding any wetting agents. By optimizing the entire process parameters from ultrasonic extraction of traditional Chinese medicine, content preparation, sol-gel, pelleting, shaping, washing, drying, and packaging, a compound soft capsule with high stability, good flowability, and clear anti-inflammatory effects is prepared. This invention solves the technical problems of easy oxidation and deterioration of camellia oil, insufficient deep processing in the camellia oil industry, and low economic added value. The resulting soft capsules can effectively inhibit pro-inflammatory factors such as TNF-α, IL-2, and IFN-γ, increase the level of the anti-inflammatory factor IL-10, and have a significant protective effect against lipopolysaccharide-induced acute kidney injury. The process of this invention is controllable and suitable for industrial production, which can significantly extend the camellia oil industry chain and enhance the competitiveness of the local woody oilseed industry.

This invention discloses a heterozygous sesquiterpene tricyclic epoxy compound derived from the strain *Arthrum oligosporum*, its preparation method, and its applications, belonging to the field of natural product chemistry. This invention provides a heterozygous sesquiterpene tricyclic epoxy compound derived from *Arthrum oligosporum* (… A.oligospora ) AOL_ s00210g57 Anthrobotrisin D, a novel heterozygous sesquiterpene tricyclic epoxy compound from a gene knockout strain, has been shown in vitro to possess excellent anti-inflammatory activity, significantly inhibiting lipopolysaccharide-induced inflammatory responses in mouse microglia. It exhibits a clear dose-dependent inhibitory trend at multiple levels, including NO release, protein and mRNA expression of inflammatory factors (TNF-α, IL-1β, IL-6), and iNOS protein and mRNA expression. Furthermore, at a concentration of 33 μM, its anti-inflammatory effect is comparable to that of the clinically proven positive drug dexamethasone, and in some aspects, it is even superior. This invention not only provides a new lead compound for the development of anti-inflammatory drugs but also opens up new directions for developing new drugs from the unique microbial resource of nematode-preying fungi.

This invention relates to a guinea pig model of chronic obstructive pulmonary disease (COPD) with chronic bronchitis, its preparation method, and its application. Specifically, this invention provides a guinea pig model of COPD with chronic bronchitis, established by subjecting guinea pigs to at least two intratracheal infusions of lipopolysaccharide (LPS) combined with repeated exposure to cigarette smoke. This results in the guinea pigs exhibiting pathophysiological characteristics consistent with those of COPD with chronic bronchitis in terms of cough sensitivity, airway inflammation, airway hypersecretion, lung function, and histopathology. This lays a solid foundation for in-depth research and drug screening of COPD with chronic bronchitis.

This application discloses a fluorescent probe for labeling the outer membrane of Gram-negative bacteria, its preparation method, and its application. The fluorescent probe uses polymyxin (with its hydrophobic tail and two amino acid residue pairs removed) as a targeting group specifically targeting the outer membrane of Gram-negative bacteria. This structure can specifically bind to the lipopolysaccharide structure in the outer membrane, and is then linked to the fluorophore rhodamine, which has switching properties, to design and synthesize a fluorescent dye. This fluorescent probe, possessing fluorescent switching properties, can be applied to super-resolution imaging of the outer membrane of Gram-negative bacteria.

The application relates to application of a furan coumarin compound shown in a formula I to prevention and / or treatment of a nervous system disease related to neuroinflammation. The furan coumarin compound has a protective effect on normoxia + lipopolysaccharide (LPS) and hypoxia + LPS combined induction of mouse stellate glial C8-D1A cell normoxia and hypoxia neuroinflammation models, can promote cell growth, inhibit production of related inflammatory factors, effectively reduce brain water content production, weight loss and key protein expression of a plateau cerebral edema model mouse, and can be developed into a medicine for preventing and / or treating neuroinflammation related diseases.

This utility model relates to biotechnology and microbiology, specifically to the production of anthrax erythrocyte antigen diagnostic solution for the indirect hemagglutination assay (IHA). The technical result achieved by this utility model is increased specificity, sensitivity, and standardization of the erythrocyte antigen diagnostic solution, and reduced conjugating agent content, all while maintaining a long shelf life. A method for obtaining an anthrax erythrocyte antigen diagnosticum, including obtaining an antigen from the culture filtrate of the vaccine strain Bacillus anthracis 55, treating formalized ram erythrocytes with a conjugating preparation, followed by sensitization of the erythrocytes with anthrax antigen, to 100.0 mg of acetone-dried bacterial mass of the anthrax vaccine strain Bacillus anthracis STI-1 add 10.0 ml of a 70% phenol solution, shake and leave in the cold at 4°C for 3 hours, then the mixture is centrifuged at 6000 rpm for 90 minutes, the supernatant liquid is drained and neutralized by adding a saturated solution of sodium carbonate until a pH of 7.1±0.1 is obtained, and to remove insoluble particles the mixture is centrifuged at 6000 rpm for 30 minutes, the resulting yellowish opalescent supernatant is placed in a laboratory dialysis bag and dialyzed against running water for 2 days and then for 24 hours against distilled water, changing the water 4-5 times; the lipopolysaccharide antigen is extracted from the dialyzed solution by adding 5 volumes of 96° ethyl alcohol and acetone 1:1; the resulting mixture is shaken and left at a temperature of 4°C for 18-20 hours, After the specified period, the mixture is centrifuged at 5000 rpm for 90 min, then the supernatant is drained, and the sediment is washed twice with 3 volumes of 96° ethyl alcohol by centrifugation at 5000 rpm for 30 min, then the sediment is dissolved in distilled water, the resulting liquid lipopolysaccharide antigen in a volume of 3.0 ml is poured into glass vials with a capacity of 20.0 ml, after which the frozen antigen in the vials is transferred to a drying chamber, pre-cooled to a temperature of minus 30°C, hermetically close the lid and turn on the vacuum pump, after creating a vacuum in the chamber, after 2 hours turn on the heating of all the plates, while the temperature of the plates after 1 hour is raised to + 28°C, this heating temperature is maintained until the end of lyophilization, while the temperature in the vial with the antigen after 13 hours is also brought to a temperature of + 28°C, when this temperature is reached, lyophilization is completed after 6 hours, then the sensitized erythrocytes are washed and preserved, the residue of atkisencitin that has not bound to the erythrocyte receptors is removed, they are washed four times for 10 minutes at 3000 rpm with a solution of Tween-80 in a dilution of 1:5000 at the rate of 25-fold volume to the erythrocyte sediment, the sediment of sensitized erythrocytes after washing is diluted with a 0.9% solution of sodium chloride pH (6.8 ± 0.1) and sodium azide to a 10% concentration of erythrocytes.

A composition comprising cells of a Parabacteroides goldsteinii strain (e.g., RV-01) and a carrier, wherein the cells comprise a population of hypo-acylated lipopolysaccharides (LPS). Also provided herein are methods for alleviating conditions such as conditions associated with aging or inflammation with the composition comprising the Parabacteroides goldsteinii cells.

The application belongs to the field of nanomaterials and biomedicine, and provides a X03 phage-cerium oxide nanoscale enzyme composite treatment platform based on chemical cross-linking of polyethylene glycol, a synergistic treatment platform integrating bactericidal and detoxification functions, namely X03@CeO2, is constructed by covalently coupling phage X03 targeting pseudomonas aeruginosa and CeO2 nanoscale enzyme with phosphatase activity, which solves the problem that antibiotic and phage therapy exacerbate systemic inflammatory storm due to massive release of lipopolysaccharide caused by bacterial lysis when killing multiple drug-resistant gram-negative bacteria. In vitro and in vivo experiments show that the complex can efficiently remove bacteria and biofilm, simultaneously degrade released LPS, significantly inhibit the production of inflammatory factors, active oxygen burst and TLR4 pathway activation, greatly improve the survival rate in a lethal sepsis mouse model and reverse multiple organ damage. The application is suitable for treating sepsis caused by drug-resistant gram-negative bacteria.

This invention relates to the field of biomedical technology, and more particularly to the application of an isoflavone compound, specifically Corylifol A, in the preparation of drugs for the prevention and / or treatment of inflammatory diseases. When used to prepare drugs for the prevention and / or treatment of inflammatory diseases, this isoflavone compound can directly bind to the IκBα protein and specifically inhibit its phosphorylation, thereby blocking the phosphorylation and nuclear translocation of the NF-κB p65 subunit, ultimately inhibiting the overactivation of the NF-κB signaling pathway. Furthermore, the isoflavone compound can significantly reduce the mortality rate of lipopolysaccharide-induced septicemia in mice, inhibit the levels of inflammatory factors in serum and lung tissue, and effectively alleviate LPS-induced acute lung injury in mice. Simultaneously, when the isoflavone compound is controlled within an effective concentration range, it exhibits no significant cytotoxicity to mouse peritoneal macrophages and can significantly inhibit the production and release of lipopolysaccharide-induced inflammatory factors IL-1β, TNF-α, and IL-6.

The invention relates to the field of biomedicine, and provides an application of a Gram-negative bacterium infection target Kdo in research and development of antibacterial drugs. An authorized antibacterial peptide Ly (PEG)-1 is used as a probe; through computer simulation, affinity determination and gene defect strain identification, the key action target is lipopolysaccharide (LPS) internal core Kdo (3-deoxy-D-mannan-octanone acid), Kdo is used as a key component of bacteria LPS and is a basis for maintaining Gram-negative bacteria cell wall integrity, LPS biosynthesis and biological activity exertion, and the Kdo is used as a key component of bacteria LPS. The deletion or modification can directly cause the loss of LPS function and the reduction of the viability of bacteria. At present, no antibacterial drug aiming at the target spot exists, the problem that in the prior art, no biomolecule capable of targeting Kdo to exert strong antibacterial activity exists is solved, and the biomolecule can be used for developing drugs for diagnosing or treating related diseases.

This invention specifically discloses a novel chalcone compound, its preparation method, pharmaceutical composition, and applications. Experimental results show that this compound exhibits significant anti-inflammatory activity in a lipopolysaccharide-stimulated RAW 264.7 cell model, significantly superior to the positive control drug dexamethasone; and in a free fatty acid-treated HepG2 cell model, it exhibits significant inhibition of lipid accumulation, significantly superior to the positive control drug obeticholic acid. It can be used to develop drugs for the treatment of non-alcoholic fatty liver disease, including but not limited to simple fatty liver, non-alcoholic steatohepatitis, and related cirrhosis.

This invention discloses a wolfberry leaf extract and its application in the preparation of acne prevention and treatment products. The invention uses specific process steps to prepare different solvent extracts of wolfberry leaves. This wolfberry leaf extract can reduce the level of lipopolysaccharide-induced inflammatory factors in Hacat cells and significantly improve acne symptoms in a rat acne lesion model. The wolfberry leaf extract provided by this invention has the potential to become a therapeutic product for acne and exhibits good safety.

The application belongs to the technical field of paper-based sensor preparation and detection application, and discloses a paper-based sensor capable of rapidly detecting lipopolysaccharide based on a smart phone. The paper-based biosensor capable of rapid detection is constructed based on a smart phone. The colorimetric performance of filter paper is combined with the characteristics of digital reconstruction of a smart phone App, and a large amount of dyeing agents are introduced through UATRP, so that the lipopolysaccharide paper-based sensor not only realizes instant and rapid detection, but also has a wider detection range and a lower detection limit. The linear detection range of the lipopolysaccharide concentration is 1-10 8 pg / mL, and the detection limit is 0.9172 pg / mL (S / N=3).

This invention provides the use of a reagent overexpressing Parp7 in the preparation of drugs for treating septic cardiomyopathy, belonging to the field of biomedical technology. This invention involves constructing a recombinant adeno-associated virus vector AAV9-F4 / 80- that specifically overexpresses PARP7 on macrophages. Parp7 The drug was intravenously injected into mice, and a septic cardiomyopathy model was established using lipopolysaccharide induction. Experimental results showed that macrophage-specific overexpression of PARP7 significantly reduced serum levels of myocardial injury markers CK-MB and cTnT, improved cardiac function indicators such as ejection fraction and fractional shortening, alleviated myocardial tissue pathological damage, and inhibited macrophage infiltration and inflammatory factors. Ifn-beta , Tnf- α , Il‑6 and Il‑1β The expression of PARP7. This invention reveals the protective role of PARP7 in septic cardiomyopathy, providing a new target and strategy for the treatment of septic cardiomyopathy.

The application discloses a compound extracted and separated from Chloranthus glaucescens and application thereof, relates to the technical field of medicinal compounds, and provides a structural formula, a preparation method and application. A novel compound is separated from Chloranthus glaucescens, the compound has a good protective effect on lipopolysaccharide-induced acute lung injury, and thus can be used for preparing an acute lung injury improvement drug.

The present application relates to the technical field of microorganism, and specifically discloses a Klebsiella pneumoniae strain for producing functional specific lipopolysaccharide and application thereof, wherein the Klebsiella pneumoniae strain for producing functional specific lipopolysaccharide is Klebsiella pneumoniae ZH2.1 (Klebsiella pneumoniae ZH2.1), the preservation number is CCTCC NO: M20251616, and the Klebsiella pneumoniae ZH2.1 is preserved in China Center for Type Culture Collection on July 16, 2025. The Klebsiella pneumoniae ZH2.1 can be applied to the treatment or improvement of type 2 diabetes or metabolic related fatty liver disease or type 2 diabetes combined with metabolic related fatty liver disease, and can be applied to drug or food screening.

The application belongs to the field of medicine and relates to application of an isoflavone compound, isoformononetin (IFM), in preparation of a medicine or health care product for preventing and treating depression; in mouse hippocampal neuron cells (HT22) or mouse microglial cells (BV2), IFM can reduce neuroinflammation caused by corticosterone (CORT) or lipopolysaccharide (LPS) and increase the expression level of brain-derived neurotrophic factor (BDNF); in a chronic mild unpredictable stress mouse depression model, IFM can relieve depression-like behavior of the mouse and reduce the inflammation level of brain tissue, indicating that IFM has a good effect of relieving depression; IFM degrades PDE4D protein by directly combining with a PDE4D target protein. The isoflavone compound IFM has the advantages of outstanding effect and high safety and is expected to develop into an effective medicine for treating and preventing depression.

The present invention relates to enriched populations of modified lipopolysaccharide (LPS) molecular species in which the C1 position of the reducing end of the lipid A domain lacks a phosphate group and is substituted with a hydrophilic moiety at the C6' position of the non-reducing end of the lipid A domain, with the proviso that the hydrophilic moiety is not a hydroxyl group. The present invention also relates to compositions comprising the enriched populations of modified LPS, and to uses of the enriched populations of naturally occurring and / or modified LPS molecular species for treating and / or preventing cancer, inflammatory or infectious diseases, and for stimulating an immune response or vaccinating a subject.

The application provides a near-infrared response magnesium-releasing and antioxidant double-layer microneedle and a preparation method and application thereof. The double-layer microneedle comprises a needle tip layer and a backing layer, the needle tip layer contains MoS2@PDA@Mg 2+ The application discloses a composite particle, which is composed of molybdenum disulfide nanosheets, surface-coated polydopamine and coordination-loaded magnesium ions. The preparation method comprises the following steps: one-step reaction of molybdenum disulfide, dopamine and magnesium salt to obtain the composite particle, and then preparation of the composite particle into a needle tip layer precursor solution together with GelMA, PVA and the like, and two-step light cross-linking molding with a backing layer precursor solution. The double-layer microneedle can rapidly release magnesium ions under near-infrared irradiation, the release amount is 4.6 times that of a non-irradiation group, can significantly scavenge DPPH, ABTS and other free radicals, can relieve cell oxidative stress induced by lipopolysaccharide, and can effectively promote new bone formation and trabecular reconstruction in a rat tooth socket model. The application realizes the synergistic effect of light-controlled magnesium release and antioxidant, and is suitable for the fields of neural microenvironment reconstruction and bone regeneration.

This invention relates to the field of biomedical technology, and in particular to an animal model of COPD combined with sarcopenia and the application of mesenchymal stem cells in the treatment of this disease. The method of constructing the model includes the following steps: (1) Pre-stimulation stage: On the first day of modeling, lipopolysaccharide (LPS) is administered via airway nebulization to initiate airway inflammation, and continuous exposure to cigarette smoke is implemented from the first day of modeling; during this period, LPS is administered again on the 10th to 14th day of modeling to enhance the persistence of inflammation; (2) Partial phenotype confirmation stage: Lung function tests or their alternative indicators are performed on the animals after the pre-stimulation ends; (3) While continuing to implement smoke exposure, dexamethasone proteolytic load and mechanical load regulation treatment are introduced simultaneously for the enrolled animals until the total modeling time reaches 4 to 6 weeks; (4) The endpoint airflow limitation index, weight loss and muscle strength loss index are detected, and the animals are deemed to have successfully constructed the model if they simultaneously meet the corresponding thresholds.

This invention presents a polyketide compound, its preparation method, and its applications. The polyketide compound Dinemasone D was isolated from the solid-state fermentation product of *Phaeosphaeria poagena*. The polyketide compound Dinemasone D obtained in this invention exhibits a strong inhibitory effect on lipopolysaccharide (LPS)-induced NO production in BV-2 microglia, with an IC50 value of [missing value]. 50 The value was 13.8 ± 0.4 μM, close to the level of quercetin.

This invention relates to a biomarker for diagnosing rheumatoid arthritis (RA) and its application, belonging to the field of biomedical technology. This invention discovered that the concentrations of lipopolysaccharide (LPS) and diamine oxidase (DAO) in the plasma of RA patients are significantly higher than those in healthy controls. Furthermore, this invention also found that three proteins derived from plasma exosomes—phospholipid invertase 1 (PLSCR1), keratin 1 (KRT1), and complement C1QC chain (C1QC)—have good diagnostic effects on RA. Combining LPS and DAO with these three proteins can significantly improve the diagnostic accuracy of RA. Therefore, applying the biomarker of this invention to the preparation of RA diagnostic products can provide a core basis for the accurate diagnosis of RA and the generation of risk assessment systems, and has translational application value in the early diagnosis of RA and the screening and precise prevention and treatment of high-risk groups.

The application relates to the field of biological medicine, and particularly relates to application of oxatomide in preparation of a medicine for preventing or treating acute lung injury. Oxatomide can reduce inflammation induced by lipopolysaccharide (LPS), and provides an alternative medicine for treating acute lung injury. Oxatomide can reduce inflammation induced by LPS in vivo or in vitro, and the reduction of inflammation includes significantly inhibiting lung inflammation induced by intratracheal administration of LPS, and significantly inhibiting production of inflammatory factors of macrophages induced by LPS.

This invention discloses a method for preparing Fe3O4-based magnetic nanomaterials. The nanomaterials use iron(III) oxide (Fe3O4) as a core, and phenylenediamine and copper are co-modified onto their surface via a stirring method. On one hand, the phenylenediamine surface is rich in functional groups, which is beneficial for subsequent functionalization modification; its aniline-like structure can effectively enhance the photothermal effect of the nanomaterials. On the other hand, after modification with copper, the nanomaterials have a high affinity for bacteria, achieving rapid enrichment and efficient capture of pathogenic bacteria through electrostatic and metal coordination interactions. Furthermore, the photothermal effect generated by this magnetic nanomaterial under infrared light irradiation can synergistically enhance its enzyme-like activity, achieving highly efficient sterilization. Most importantly, this material can also efficiently remove harmful products generated after bacterial lysis, including peptidoglycan and lipopolysaccharide. This invention effectively solves the technical defects of traditional antibacterial materials, such as limited functionality and inability to remove toxic lysis products, demonstrating strong practicality and broad application prospects.